Spanish immune thrombocytopenia registry
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This study collects data from people with immune thrombocytopenia (a condition where the immune system destroys platelets, causing low blood counts). It aims to better understand and track the disease over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 2 months old
- You have been diagnosed with immune thrombocytopenia or a similar platelet problem since 2015
- Your platelet count is less than 100 x 10^9/L
- You have given or can give consent to participate (or are a patient who passed away after December 31, 2015)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study helps doctors better understand immune thrombocytopenia (ITP) by collecting basic patient information and, if you agree, storing blood samples. It may help future care decisions and research for people with ITP.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
This Phase 2 study tests how safe and effective PF-06835375 is for people with primary immune thrombocytopenia (ITP), a condition where platelet counts are too low. It may help reduce bleeding risk by improving platelet levels, depending on the results.
This is a real-world registry that collects information about people diagnosed with thrombotic thrombocytopenic purpura (TTP) in Spain and Portugal. It helps researchers understand TTP patterns and outcomes, and participation is voluntary.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
Hear when a new Primary Immune Thrombocytopenia (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.